• Publications
  • Influence
Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells*
TLDR
It is shown that fAβ and sAβ interact differently with microglia but that after internalization a large fraction of both are released without degradation. Expand
Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules
TLDR
Proteolytic activity in lysosomes of macrophages may be excessive, compared with fibroblasts and B cells, and destroys epitopes of the C5 protein before they can gain access to MHC class II molecules, suggesting there are inherent differences in presentation pathways between antigen‐presenting cell types. Expand
Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia*
TLDR
Comparing internalization by microglia of fAβ microaggregates to that of anti-Aβ-antibody-coated fA β (IgG-fAβ) microaggRegates and found that the uptake of the latter is increased, suggest that, in vivo, several different microglial receptors may play a part in internalizing fAα, but the involvement of other receptors may not increase the degradation of f aβ. Expand
The HSC73 molecular chaperone: involvement in MHC class II antigen presentation.
TLDR
It is shown that heat shock cognate protein (HSC)73, a constitutively expressed member of the HSP70 family, could be a candidate for chaperone activity within the MHC class II presentation pathway. Expand
Uptake of fibrillar β-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice
TLDR
To charaterize the receptors involved in binding fibrillar amyloid A-beta (fAβ), the uptake of fAβ in microglia from wildtype and MSR-A knockout mice was compared to show a significant reduction in the uptake, which suggests that fA β gets internalized mostly byMSR-As inmicroglia. Expand
Drug delivery: First class delivery
  • M. Brazil
  • Medicine
  • Nature Reviews Drug Discovery
  • 2002
Long-term study proposed for COX2 inhibitors
  • M. Brazil
  • Medicine
  • Nature Reviews Drug Discovery
  • 1 April 2005
TLDR
To truly evaluate the risks of the COX2 inhibitors, more needs to be known about older treatments than is known about current treatments. Expand
Neurodegenrative disease: Come on everybody, do the congo!
  • M. Brazil
  • Biology, Medicine
  • Nature Reviews Drug Discovery
  • 1 April 2003
HIV-1: Viral assembly inhibitors on the horizon
  • M. Brazil
  • Medicine
  • Nature Reviews Drug Discovery
  • 24 August 2005
TLDR
A molecule that interferes with the formation of HIV particles in vitro is identified, which could lead to the development of a new class of HIV drugs that slow or prevent the progression of HIV in patients, according to two papers in Nature Structural & Molecular Biology. Expand
Drug delivery: Controlling the flow
  • M. Brazil
  • Medicine
  • Nature Reviews Drug Discovery
  • 1 July 2003
...
1
2
3
4
5
...